Shorts

Amy E. Krambeck, MD, on 3- vs 2-lobe enucleation for BPH
1:34
Amy E. Krambeck, MD, on 3- vs 2-lobe enucleation for BPH
a day ago
by
Amy E. Krambeck, MD
Mohit Khera, MD, MBA, MPH, on why FDA TRT announcement is a “big win”
0:20
Mohit Khera, MD, MBA, MPH, on why FDA TRT announcement is a “big win”
2 days ago
by
Mohit Khera, MD, MBA, MPH
The UroOnc Minute: Dr. Alfonso Gómez de Liaño Lista on implications of KEYNOTE-B15
1:01
The UroOnc Minute: Dr. Alfonso Gómez de Liaño Lista on implications of KEYNOTE-B15
3 days ago
by
Adam B. Weiner, MD(+1 more)
Jesse N. Mills, MD, on why urologists need to be at the forefront of treating low libido
0:21
Jesse N. Mills, MD, on why urologists need to be at the forefront of treating low libido
4 days ago
by
Jesse N. Mills, MD
Landon Trost, MD, on the significance of the FDA announcement on idiopathic hypogonadism
1:28
Landon Trost, MD, on the significance of the FDA announcement on idiopathic hypogonadism
7 days ago
by
Landon W. Trost, MD
Mohit Khera, MD, MBA, MPH, reacts to FDA announcement on TRT and idiopathic hypogonadism
0:43
Mohit Khera, MD, MBA, MPH, reacts to FDA announcement on TRT and idiopathic hypogonadism
8 days ago
by
Mohit Khera, MD, MBA, MPH
The Expert APProach: Melissa Kestler, DNP, FNP-BC, on working in a stone clinic
1:01
The Expert APProach: Melissa Kestler, DNP, FNP-BC, on working in a stone clinic
8 days ago
by
Joy Maulik, CRNP(+1 more)
James R. Porter, MD, on the telementoring capabilities of the Hugo RAS
0:51
James R. Porter, MD, on the telementoring capabilities of the Hugo RAS
9 days ago
by
James R. Porter, MD
Pearls & Perspectives: Normalizing sexual wellness conversations
1:12
Pearls & Perspectives: Normalizing sexual wellness conversations
10 days ago
by
Amy M. Pearlman, MD
Jennifer Miles-Thomas, MD, discusses areas of opportunity for urology APPs
1:13
Jennifer Miles-Thomas, MD, discusses areas of opportunity for urology APPs
11 days ago
by
Jennifer Miles-Thomas, MD, URPS, MBA
The Expert APProach: Preparing the Next Generation of APPs
0:59
The Expert APProach: Preparing the Next Generation of APPs
14 days ago
by
Joy Maulik, CRNP(+1 more)
Akanksha Mehta, MD, on counseling men on vasectomy safety
1:03
Akanksha Mehta, MD, on counseling men on vasectomy safety
15 days ago
by
Akanksha Mehta, MD, MS(+1 more)
Jonathan Anker, MD, on bladder-sparing approach in patients with MIBC
1:10
Jonathan Anker, MD, on bladder-sparing approach in patients with MIBC
16 days ago
by
Jonathan F. Anker, MD, PhD
Daniel J. George, MD, on PTEN loss and prostate cancer prognosis
1:15
Daniel J. George, MD, on PTEN loss and prostate cancer prognosis
17 days ago
by
Daniel J. George, MD
Alexandra Drakaki, MD, on misdiagnosis of bladder cancer in women
1:02
Alexandra Drakaki, MD, on misdiagnosis of bladder cancer in women
18 days ago
by
Alexandra Drakaki, MD, PhD
Pearls & Perspectives: What is “normal” urination frequency?
1:02
Pearls & Perspectives: What is “normal” urination frequency?
21 days ago
by
Amy M. Pearlman, MD
Giulia Almiron da R. Soares on social media and urology recruitment
1:03
Giulia Almiron da R. Soares on social media and urology recruitment
22 days ago
by
Giulia Almiron da R. Soares
Jared S. Winoker, MD, on research comparing CVAC 2.0 vs FANS
0:23
Jared S. Winoker, MD, on research comparing CVAC 2.0 vs FANS
23 days ago
by
Jared S. Winoker, MD
James R. Porter, MD, discusses haptics and the Hugo RAS system
1:06
James R. Porter, MD, discusses haptics and the Hugo RAS system
24 days ago
by
James R. Porter, MD
Matthias Saar, MD, outlines the rationale for the phase 2 INDUCTA trial in prostate cancer
0:37
Matthias Saar, MD, outlines the rationale for the phase 2 INDUCTA trial in prostate cancer
25 days ago
by
Matthias Saar, MD
Pearls & Perspectives: The trouble with voiding diaries
1:13
Pearls & Perspectives: The trouble with voiding diaries
a month ago
by
Amy M. Pearlman, MD
Is PCNL dead? with Ben H. Chew, MD, MSc, FRCSC
0:29
Is PCNL dead? with Ben H. Chew, MD, MSc, FRCSC
a month ago
by
Ben H. Chew, MD, MSc
Alicia Morgans, MD, discusses cancer control with enzalutamide, apalutamide
1:12
Alicia Morgans, MD, discusses cancer control with enzalutamide, apalutamide
a month ago
by
Alicia Morgans, MD, MPH
Bogdana Schmidt, MD, MPH, on who could benefit most from ICI plus BCG in high-risk NMIBC
1:05
Bogdana Schmidt, MD, MPH, on who could benefit most from ICI plus BCG in high-risk NMIBC
a month ago
by
Bogdana Schmidt, MD, MPH
Neha Vapiwala, MD, explores the biggest prostate cancer takeaways from ASCO GU 2026
1:19
Neha Vapiwala, MD, explores the biggest prostate cancer takeaways from ASCO GU 2026
a month ago
by
Neha Vapiwala, MD, FASTRO
Christopher Pieczonka, MD, on what’s next for NAI plus BCG in BCG-naïve NMIBC
1:12
Christopher Pieczonka, MD, on what’s next for NAI plus BCG in BCG-naïve NMIBC
a month ago
by
Christopher Pieczonka, MD
Sara Coca Membribes, MD, on what’s needed to refine the role of BCG-ICI combinations in NMIBC
0:42
Sara Coca Membribes, MD, on what’s needed to refine the role of BCG-ICI combinations in NMIBC
a month ago
by
Sara Coca Membribes, MD
Jean-Nicolas Cornu, MD, PhD, FEBU, on the patient population of VAPEUR-RCT in BPH
0:45
Jean-Nicolas Cornu, MD, PhD, FEBU, on the patient population of VAPEUR-RCT in BPH
a month ago
by
Jean-Nicolas Cornu, MD, PhD, FEBU
Antoni Vilaseca Cabo, MD, on the pharmacokinetics of erda-iDRS in NMIBC
0:41
Antoni Vilaseca Cabo, MD, on the pharmacokinetics of erda-iDRS in NMIBC
a month ago
by
Antoni Vilaseca Cabo, MD
Daniel J. George, MD, on the need for caregiver support in prostate cancer
0:48
Daniel J. George, MD, on the need for caregiver support in prostate cancer
a month ago
by
Daniel J. George, MD